KALA - Kala Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
KALA price evolution
KALA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.2 | $54.2 | $48.48 | $50.9 |
| Short term investments | ||||
| Net receivables | $3.46 | $0.24 | ||
| Inventory | ||||
| Total current assets | $51.28 | $58.85 | $50.09 | $52.87 |
| Long term investments | $0.3 | |||
| Property, plant & equipment | $2.54 | $2.48 | $2.66 | $2.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.75 | $2.95 | $3.08 | |
| Total investments | $0.3 | |||
| Total assets | $54.08 | $61.61 | $53.03 | $55.95 |
| Current liabilities | ||||
| Accounts payable | $0.71 | $0.67 | $0.73 | $0.92 |
| Deferred revenue | $2.26 | $1.07 | ||
| Short long term debt | $12.34 | $6.34 | $0.33 | |
| Total current liabilities | $23.87 | $19.19 | $11.88 | $8.35 |
| Long term debt | $17.16 | $24.46 | $30.23 | $35.99 |
| Total noncurrent liabilities | $28.7 | $34.49 | $40.1 | |
| Total debt | $36.8 | $36.56 | $36.32 | |
| Total liabilities | $47.22 | $47.89 | $46.37 | $48.45 |
| Shareholders' equity | ||||
| Retained earnings | -$659.75 | -$650.79 | -$641.22 | -$629.41 |
| Other shareholder equity | ||||
| Total shareholder equity | $13.72 | $6.66 | $7.5 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $50.9 | $70.5 | $94.18 | $77.26 |
| Short term investments | $76.28 | |||
| Net receivables | $0.24 | $1.1 | $15.35 | $9.6 |
| Inventory | $18.22 | $11.45 | ||
| Total current assets | $52.87 | $85.94 | $124.37 | $171.38 |
| Long term investments | $0.3 | $0.46 | $1.46 | $12.99 |
| Property, plant & equipment | $2.78 | $0.42 | $4.02 | $31.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.08 | $0.88 | $15.06 | $50.23 |
| Total investments | $0.3 | $0.46 | $1.46 | $89.27 |
| Total assets | $55.95 | $86.82 | $139.43 | $221.61 |
| Current liabilities | ||||
| Accounts payable | $0.92 | $2.83 | $4.9 | $1.72 |
| Deferred revenue | $1.07 | |||
| Short long term debt | $0.33 | $5.01 | $0.71 | $1.53 |
| Total current liabilities | $8.35 | $25.68 | $37.42 | $22.23 |
| Long term debt | $35.99 | $37.94 | $79.48 | $99.39 |
| Total noncurrent liabilities | $40.1 | $42.16 | $85.2 | $99.39 |
| Total debt | $36.32 | $42.95 | $80.19 | $100.92 |
| Total liabilities | $48.45 | $67.85 | $122.62 | $121.61 |
| Shareholders' equity | ||||
| Retained earnings | -$629.41 | -$587.21 | -$542.39 | -$399.78 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $7.5 | $18.97 | $16.8 | $100 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $5.32 | $6.35 | $4.72 | |
| Selling, general & administrative | $4.32 | $5.42 | $4.62 | |
| Total operating expenses | $9.63 | $11.77 | $9.34 | |
| Operating income | -$9.63 | -$11.77 | -$9.34 | |
| Income from continuing operations | ||||
| EBIT | -$8.12 | -$10.35 | -$7.16 | |
| Income tax expense | ||||
| Interest expense | $1.46 | $1.46 | $1.47 | |
| Net income | ||||
| Net income | -$9.58 | -$11.81 | -$8.63 | |
| Income (for common shares) | -$9.58 | -$11.81 | -$8.63 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.89 | $11.24 | $6.36 | |
| Cost of revenue | $2.56 | $4.1 | $3.17 | |
| Gross Profit | $1.33 | $7.14 | $3.19 | |
| Operating activities | ||||
| Research & development | $18.59 | $17.65 | $11.52 | $18.35 |
| Selling, general & administrative | $20.57 | $65.03 | $105.06 | $81.07 |
| Total operating expenses | $38.92 | $83.33 | $137.39 | $99.42 |
| Operating income | -$38.92 | -$81.99 | -$130.25 | -$96.23 |
| Income from continuing operations | ||||
| EBIT | -$36.38 | -$37.56 | -$134.22 | -$95.74 |
| Income tax expense | ||||
| Interest expense | $5.81 | $7.27 | $8.38 | $8.59 |
| Net income | ||||
| Net income | -$42.2 | -$44.82 | -$142.6 | -$104.33 |
| Income (for common shares) | -$42.2 | -$44.82 | -$142.6 | -$104.33 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$9.58 | -$11.81 | -$8.63 | |
| Operating activities | ||||
| Depreciation | $0.14 | $0.15 | $0.15 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.88 | $2.38 | $2.37 | |
| Total cash flows from operations | -$9.21 | -$10.84 | -$7.7 | |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.01 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$0.14 | -$0.04 | -$0.01 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $14.97 | $0.02 | $0.57 | |
| Net borrowings | ||||
| Total cash flows from financing | $23.23 | $14.97 | $8.44 | $2.54 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.69 | $5.72 | -$2.42 | -$5.17 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$42.2 | -$44.82 | -$142.6 | -$104.33 |
| Operating activities | ||||
| Depreciation | $0.47 | $0.98 | $2.31 | $2.84 |
| Business acquisitions & disposals | $62.91 | -$4.65 | ||
| Stock-based compensation | $7.46 | $7.01 | $16.09 | $13.31 |
| Total cash flows from operations | -$27.93 | -$78.91 | -$108.23 | -$90.69 |
| Investing activities | ||||
| Capital expenditures | -$0.56 | -$0.2 | -$0.79 | -$1.94 |
| Investments | $0.13 | $0.01 | $76.25 | -$76.27 |
| Total cash flows from investing | -$0.43 | $62.72 | $70.8 | -$78.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $18.58 | $32.1 | $42.82 | $160.66 |
| Net borrowings | -$10 | -$40.04 | -$0.26 | -$0.03 |
| Total cash flows from financing | $8.51 | -$7.94 | $42.55 | $160.63 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$19.85 | -$24.13 | $5.12 | -$8.28 |
News
|
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
Zacks · via Yahoo Finance
16 Nov 2023
|
|
10 Best Stocks to Buy for a Quick Return
Insider Monkey via Yahoo Finance
11 May 2023
|
|
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
Zacks via Yahoo Finance
19 Apr 2023
|
|
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
Zacks via Yahoo Finance
19 Apr 2023
|
|
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Zacks via Yahoo Finance
17 Apr 2023
|
|
KALA Up on Fast Track Designation to Lead Ocular Candidate
Zacks via Yahoo Finance
12 Apr 2023
|
|
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
Zacks via Yahoo Finance
12 Apr 2023
|
|
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
Zacks via Yahoo Finance
11 Apr 2023
|
|
10 Eyecare Stocks with Upside Potential
Insider Monkey via Yahoo Finance
5 Apr 2023
|
|
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
Zacks via Yahoo Finance
4 Apr 2023
|
Fundamentals
| Market cap | $3.47M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 4.61M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 10.67 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 6.46 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.15 |
| Quick ratio | N/A |